effect overlay
activetrials
Stroke
Stroke
ALNylam

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA)

HREC: 2024.264
Principal Investigator: A/Prof Nawaf Yassi
Coordinator contact: David Jackson
Funding: Commercial
Stroke
Stroke
EMU: EMVision Validation Study

Multi-Centre, Prospective, Consecutive, Paired Diagnosis, Diagnostic Performance Study of the EMVision emu™ Brain Scanner in the Detection of Intracranial Haemorrhage in Suspected Stroke Patients (The “EMU” Study)

HREC: 2025.052
Principal Investigator: Dr Anna Balabanski
Coordinator contact:
Funding: Commercial